⚗️ Metabolic Disorder

Gaucher Disease

Also known as: Gaucher's Disease, Glucocerebrosidase Deficiency, GD

Gaucher disease is an inherited metabolic disorder caused by a deficiency of the enzyme glucocerebrosidase. This leads to accumulation of fatty substances in cells and organs, particularly the spleen, liver, and bone marrow.

ICD-10: E75.22 Orphanet: ORPHA355 OMIM: 230800
👥 1 in 40,000 to 60,000 (1 in 450 Ashkenazi Jewish) Prevalence
🔬 52 Active Trials

Gaucher disease happens when the body can't properly clean up certain fats inside cells. These fats pile up and make the liver and spleen grow too big, and can make bones weak. Doctors can give special medicines that help the body clean up these fats.

Signs & Symptoms

  • Enlarged spleen (splenomegaly)
  • Enlarged liver (hepatomegaly)
  • Bone pain and fractures
  • Easy bruising
  • Fatigue
  • Anemia
  • Low platelet count
  • Delayed growth in children
  • Neurological symptoms (Type 2 and 3)

Treatment Options

MEDICATION FDA Approved

Imiglucerase (Cerezyme)

HIGHLY EFFECTIVE Approved 1994
MEDICATION FDA Approved

Velaglucerase alfa (VPRIV)

HIGHLY EFFECTIVE Approved 2010
MEDICATION FDA Approved

Taliglucerase alfa (Elelyso)

HIGHLY EFFECTIVE Approved 2012
MEDICATION FDA Approved

Eliglustat (Cerdelga)

HIGHLY EFFECTIVE Approved 2014
MEDICATION FDA Approved

Miglustat (Zavesca)

MODERATELY EFFECTIVE Approved 2003
TRANSPLANT FDA Approved

Bone marrow transplant

CURATIVE

Diagnosis

  • Enzyme activity assay (glucocerebrosidase)
  • Genetic testing for GBA mutations
  • Bone marrow biopsy showing Gaucher cells
  • Complete blood count
  • MRI for bone involvement
  • Liver/spleen volume measurement

History

Philippe Gaucher first described the disease in 1882. The enzymatic defect was identified in 1965 by Roscoe Brady at NIH. The development of enzyme replacement therapy by Brady's team in the 1990s revolutionized treatment and served as a model for treating other lysosomal storage disorders.

Recent Breakthroughs

2024

Gene therapy clinical trials advance

AAV-based gene therapy trials show sustained enzyme production and potential for one-time treatment.

2023

New substrate reduction therapies

Next-generation SRT drugs with improved brain penetration show promise for neuronopathic forms.

2022

Parkinson's disease connection clarified

Research reveals molecular mechanisms linking GBA mutations to Parkinson's pathology.